Granted Patent B2

US 9,446,144 · App. 14/145,745 · Granted Sep 20, 2016

Inventors: Geert-Jan Boons (Athens, GA); Therese Buskas (Athens, GA); Sampat Ingale (San Diego, CA); Margaretha Wolfert (Athens, GA)

Assignee: University of Georgia Research Foundation, Inc.

A61K47/4833A61K9/127A61K39/0008A61K39/0011A61K39/385C07K9/00C07K14/22C07K14/4727C07K16/3076C07K16/44A61K38/00A61K2039/545A61K2039/55555A61K2039/57A61K2039/6018A61K2039/6075C07K2317/34C12N2740/16011C12N2740/16134G01N2400/02G01N2800/042G01N2800/2821

Abstract

Claims (15)

1. A glycolipopeptide comprising:

at least one carbohydrate component comprising a MUC-1 glycopeptide comprising at least one B-epitope;

at least one peptide component comprising a microbial peptide comprising at least one T-epitope; and

at least one lipid component comprising Pam 3 CysSK n , wherein n=0, 1, 2, 3, 4, or 5.

2. The glycolipopeptide of claim 1 wherein the T-epitope comprises a helper T epitope.

3. The glycolipopeptide of claim 1 wherein the T-epitope comprises amino acid sequence KLFAVWKITYKDT (SEQ ID NO:3).

4. The glycolipopeptide of claim 1 wherein the glycopeptide comprises at least one O-GalNAc moiety.

5. The glycolipopeptide of claim 1 wherein the MUC-1 glycopeptide comprises the amino acid sequence TSAPDT(α-D-GalNAc)RPAP.

6. The glycolipopeptide of claim 1 wherein the lipid component comprises Pam 3 CysSK 4 .

7. A pharmaceutical composition comprising:

the glycolipopeptide of claim 1 and

a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 comprising a liposome comprising the glycolipopeptide.

9. The glycolipopeptide of claim 1 , wherein the glycolipopeptide comprises an N-terminus comprising the lipid component.

10. The glycolipopeptide of claim 1 , wherein the lipid component comprises Pam 3 CysSK 4 , the peptide component comprises KLFAVWKITYKDT (SEQ ID NO:3), and the carbohydrate component comprises TSAPDT-(αGalNAc)-RPAP.

Assignments (2)

Continuity (9)